Search engine for discovering works of Art, research articles, and books related to Art and Culture
ShareThis
Javascript must be enabled to continue!

Lupus Unmasked: The Infliximab Connection

View through CrossRef
Drug-induced lupus erythematosus (DILE) is an autoimmune phenomenon where the symptoms are similar to systemic lupus erythematosus (SLE) after exposure to certain drugs. While DILE tends to be less severe than SLE, the diagnosis can be challenging. Infliximab, a TNF-alpha inhibitor, is widely prescribed for autoimmune conditions such as Crohn’s disease, rheumatoid arthritis, and ankylosing spondylitis. Although rare, Infliximab can cause Drug-Induced Lupus Erythematosus (DILE). This case report presents a 67-year-old male patient who developed this unconventional adverse drug reaction. It emphasizes the importance of vigilant monitoring, early detection, and prompt intervention to prevent long-term complications in patients receiving Infliximab treatment.
Title: Lupus Unmasked: The Infliximab Connection
Description:
Drug-induced lupus erythematosus (DILE) is an autoimmune phenomenon where the symptoms are similar to systemic lupus erythematosus (SLE) after exposure to certain drugs.
While DILE tends to be less severe than SLE, the diagnosis can be challenging.
Infliximab, a TNF-alpha inhibitor, is widely prescribed for autoimmune conditions such as Crohn’s disease, rheumatoid arthritis, and ankylosing spondylitis.
Although rare, Infliximab can cause Drug-Induced Lupus Erythematosus (DILE).
This case report presents a 67-year-old male patient who developed this unconventional adverse drug reaction.
It emphasizes the importance of vigilant monitoring, early detection, and prompt intervention to prevent long-term complications in patients receiving Infliximab treatment.

Related Results

Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Spectrum of cutaneous lupus erythematosus in South Africans with systemic lupus erythematosus
Background Cutaneous involvement is very common in systemic lupus erythematosus. We describe the prevalence and spectrum of lupus-specific (cutaneous lupus erythematosus) and non-s...
Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication
Comparison of SB2-Infliximab With Originator-Infliximab in the Measurement of Serum Concentrations: A Short Communication
Background: The optimal use of infliximab depends on the measurement of trough levels with subsequent appropriate dose adjustment. With the introduction of biosimilars,...
A Study Investigating the Association of Dermatological and Infusion Reactions to Infliximab and Infliximab Trough Levels
A Study Investigating the Association of Dermatological and Infusion Reactions to Infliximab and Infliximab Trough Levels
BACKGROUND: Although infliximab is an effective therapy for inflammatory bowel disease (IBD), it is associated with dermatological events and infusion reactions. It is not known wh...
Lupus: Public Education
Lupus: Public Education
Lupus is a chronic autoimmune disease that can affect various parts of the body, including the skin, joints, kidneys, heart, and brain. In lupus, the immune system mistakenly attac...

Back to Top